Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 17/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746974 | 0.86 | HSD11B1 (0.69) | HSD11B1NR1I2NPC1ALDH1A1HPGD | |
| SCHEMBL17111049 | 0.84 | HSD11B1 (0.58) | HSD11B1NR1I2NPC1ALDH1A1HPGD | |
| SCHEMBL2747350 | 0.83 | HSD11B1 (0.83) | HSD11B1 | |
| SCHEMBL2747248 | 0.80 | HSD11B1 (0.78) | HSD11B1 | |
| SCHEMBL2747037 | 0.76 | HSD11B1 (0.70) | HSD11B1NR1I2 | |
| SCHEMBL2748143 | 0.75 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL2746796 | 0.74 | HSD11B1 (0.66) | HSD11B1 | |
| SCHEMBL14006043 | 0.74 | HSD11B1 (0.83) | HSD11B1ALDH1A1HPGD | |
| SCHEMBL17111060 | 0.73 | HSD11B1 (0.61) | HSD11B1NR1I2NPC1ALDH1A1HPGD | |
| SCHEMBL2747775 | 0.72 | HSD11B1 (0.64) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178546-B2 | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | claimed |
| US-20100256387-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2010-10-07 | — | — | US | claimed |
| US-20080255216-A1 | Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME CORP. | 2008-10-16 | — | — | US | claimed |
| EP-1732904-A4 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO INC (US) | 2007-11-14 | — | — | EP | claimed |
| EP-1732904-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | Merck & Co., Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2005097759-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-8178546-B2 | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100256387-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2010-10-07 | — | — | US | disclosed |
| US-20080255216-A1 | Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME CORP. | 2008-10-16 | — | — | US | disclosed |
| EP-1732904-A4 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO INC (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1732904-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | Merck & Co., Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097759-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256387-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885NR1I2 70/4885NPC1 680/4885 |
| US-20080255216-A1 | Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885NR1I2 95/4885NPC1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.